Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) have announced that the European Medicines Agency (EMA) has validated their marketing authorization applications (MAA) for HLX14, an investigational biosimilar for Prolia and Xgeva (denosumab). This validation marks a significant achievement for both companies as they continue to expand their product portfolio in the field of osteoporosis treatment.
Shanghai Henlius Biotech, a leading biopharmaceutical company specializing in the development and commercialization of biosimilar and innovative drugs, has partnered with Organon, a global healthcare company, to jointly develop the HLX14 biosimilar candidate.
Denosumab, the active component of Prolia and Xgeva, has already been approved in various countries and regions under different brand names for multiple indications, including the treatment of osteoporosis in women. With the validation of the MAA by the EMA, the HLX14 biosimilar is set to provide a highly effective and more accessible alternative for patients suffering from osteoporosis.
Biosimilars are biologic medicines that are highly similar to existing approved biological drugs, with no clinically meaningful differences in terms of safety and efficacy. They offer an opportunity for patients to access high-quality treatments while reducing healthcare costs. The approval of HLX14 by the EMA signifies a step forward in ensuring broader patient access to denosumab.
The partnership between Shanghai Henlius Biotech and Organon leverages their respective strengths in research, development, manufacturing, and commercialization to bring innovative and cost-effective treatments to patients worldwide. The validation of the MAA for HLX14 by the EMA reaffirms the companies’ commitment to providing high-quality and affordable treatment options for osteoporosis patients.
Shanghai Henlius Biotech, with its state-of-the-art manufacturing facilities and extensive research capabilities, has demonstrated its commitment to the development of biosimilars. The company’s vision is to make high-quality biologics accessible to patients around the globe, ensuring that they receive the best possible healthcare outcomes.
Organon, on the other hand, has a rich heritage in women’s health and a strong global presence. By partnering with Shanghai Henlius Biotech, Organon aims to further expand its reach in the field of bone health and provide innovative solutions to improve the lives of patients.
Conclusion:
The validation of the marketing authorization applications for HLX14 biosimilar by the European Medicines Agency is a significant milestone for Shanghai Henlius Biotech and Organon. This achievement signifies their commitment to providing high-quality and affordable treatment options for patients suffering from osteoporosis. The collaboration between the two companies highlights the importance of biosimilars in expanding patient access to innovative and effective therapies. With HLX14’s approval, more patients will have access to denosumab, thereby addressing the unmet medical needs of individuals with osteoporosis.
Comments